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mixture incubated for 90 min at 37 o C. The incubations were stopped by addition of 1 volume of MeOH and cooled on ice. Water was then added to give a final concentration of MeOH of 15% and the mixture was centrifuged. The supernatant was subjected to solid-phase extraction (SPE) as described previously (22) using a C 18 SepPak cartridge (Waters Associates, Milford, MA) that had been pretreated with MeOH and water. The cartridge was eluted successively with 15% MeOH, water, and petroleum ether prior to elution of eicosanoids with methyl formate. The methyl formate was then removed using a rotary evaporator and the residue dissolved in a small volume of ethanol prior to further analysis.
Processing of urine samples for MS analysis.
nPF 4α α α α -VI -Urine was collected from 20 healthy individuals, evenly divided between males and females.
Samples were immediately frozen at -80 o C until further processing. After thawing, 10 ng [ 2 H 4 ]-nPF 4α -VI (synthesized as described previously (21)) was added to 2-ml aliquots, which were mixed and allowed to equilibrate for 15 min at room temperature. The sample was extracted by SPE on a StrataX cartridge, (Phenomenex, Torrance, CA), which had been conditioned with 1 ml of acetonitrile (MeCN) followed by 1 ml H 2 O. The sample was then applied to the cartridge, which was washed successively with H 2 O (1 ml) and 5% MeCN in H 2 O (1 ml), dried by applying a vacuum for 15 min, and eluted with 1 ml of 5% MeCN in EtOAc. The eluate was dried under a gentle stream of nitrogen, and the sample stored in 40 µl MeCN at -80 o C until analysis, at which time H 2 O (160 µl) was added and the sample was filtered in a Costar Spin-X HPLC filter (0.2 µm nylon; Corning Inc, Corning, NY).
iPF 3α α α α -VI (Group I) -Urine was obtained from 6 healthy individuals, 3 males, 3 females. Samples were immediately frozen at -80 o C until further processing. After thawing, 2-ml aliquots were taken and to each was added 6.9 ng of [ 2 H 4 ]-iPF 3α -VI and 10 ng of the methoxime derivative of 2,3-dinor-6-keto-PGF 1α
(d6k-PGF 1α -MO). The samples were mixed, allowed to equilibrate for 15 min at room temperature, and extracted by SPE on StrataX cartridges as described above. The eluate was dried under a gentle stream of nitrogen, dissolved in 1 ml 75% EtOAc in hexane, and applied to a diol SPE cartridge (Bond Elut 2OH;
Varian, Palo Alto, CA), which was washed with 1 ml of 75% EtOAc in hexane and eluted with 1 ml of by guest, on October 14, 2017 www.jlr.org Downloaded from 5% MeCN in EtOAc containing 0.1% acetic acid. Samples were then dried under nitrogen and dissolved in 100 µl of 10% MeCN in water for injection onto a 150 x 2 mm HyperClone 5 µm C18 BDS column (Phenomenex, Torrence, CA) using a linear gradient between 10 and 50% solvent B over 20 min at a flow rate of 200 µL/min. Solvent A was water:acetic acid (100:0.005), adjusted to pH 5.7 with ammonium hydroxide, whereas solvent B was MeCN:MeOH:acetic acid (95:5:0.005). The transition monitored was m/z 370 m/z 150 (d6k-PGF 1α -MO). The elution time of d6k-PGF 1α -MO served to predict the elution time of iPF 3α -VI. One minute after the apex of the d6k-PGF 1α -MO peak, the column eluate was diverted from the mass spectrometer and collected for a period of 0.6 min. Samples were split into two equal portions for quantitation of iPF 3α -VI by GC/MS and LC/MS/MS as described below.
iPF 3α -VI (Group II) -Urine from 20 healthy individuals (see above) was thawed, 1-ml aliquots were removed, and to each was added 7. The urine samples were obtained with the informed consent of the donors.
Gas chromatography/mass spectrometry. GC/MS was done on a Hewlett-Packard 5973 mass spectrometer equipped with a chemical ionization source coupled to an HP 6890 GC. The instrument was operated in the electron capture/negative ion (ECNI) mode, using ammonia as the moderating gas. The 
Liquid chromatography/tandem mass spectrometry (LC/MS/MS).
All LC/MS/MS was performed using a Thermo-Finnigan TSQ Quantum Ultra AM (Thermo Electron Corp.), except for the Group I study on iPF 3α -VI, which was performed using a Micromass Ultima instrument (Waters, Milford, MA). In both by guest, on October 14, 2017 www.jlr.org
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cases, the mass spectrometer was interfaced with two Shimadzu LC-10ADvp pumps (Shimadzu, Columbia, MD) a Shimadzu SCL-10Avp system controller, and a CTC Analytics HTC PAL autosampler (LEAP Technologies, Carrboro, NC). All LC/MS/MS analyses were performed in the negative ion electrospray mode using Argon, 1.5 mTorr, as the collision gas. Quantitation was by peak area ratios.
Mobile phases for HPLC were as described above. The flow rate was 0.2 ml/min. All LC conditions and MS/MS tuning parameters were optimized by injection or infusion of authentic synthetic standards. GC/MS quantitation of iPF 3α α α α -VI from urine. Samples were dried under nitrogen and the PFB ester, TMS ether derivatives were prepared as described above. SIM was used, monitoring m/z 567 for iPF 3α -VI and m/z 571 for the tetradeuterated analog. Quantitation was by peak area ratios. the completion of the bottom side chain was done differently than the non-deuterated analog as can be seen in Fig. 3 (transformation 18 to 20) . In order to spare the deuterated synthon 19, the introduction of the deuterium piece was effected at the last stage. The structures of both compounds were confirmed by
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NMR. An analysis of the deuterium content of the deuterated analog expressed as the ratio of 2 H 0 / 2 H 4 , determined by GC/MS, was 0.0009.
Measurement of nPF 4α -VI in urine
We attempted to measure the levels of nPF 4α -VI in urine samples from healthy subjects by LC/MS/MS, but were unable to detect this neuroprostane in any of the 20 samples tested (Fig. 4A ). In contrast, we were easily able to detect a small amount (100 pg/ml) of exogenous synthetic nPF 4α -VI that had been added to the same sample (Fig. 4B ). As expected, the tetradeuterated analog had a retention time slightly shorter than that of the unlabeled compound. The retention time of both the labeled and unlabeled compounds were confirmed by separate analysis of chemically synthesized standards. Note that some of the samples exhibited a small peak near the retention time of endogenous nPF 4 α -VI. When two other ion transitions characteristic of the fragmentation of nPF 4 α -VI were monitored (m/z 377 199 and m/z 377 359), it was clear that this peak did not originate from authentic nPF 4 α -VI.
Conversion of nPF 4α -VI to iPF 3α -VI by β β β β-oxidation
In view of the presence of DHA and neuroprostanes in the brain, we were surprised to find nPF 4α -VI to be undetectable in urine. We speculated that this may be due to its metabolism by β-oxidation, and to test In contrast to nPF 4α -VI, iPF 3α -VI was quite resistant to metabolism by β-oxidation. Following incubation with a rat liver homogenate under identical conditions to those described above and analysis by LC/MS/MS, the only major component observed was the unmetabolized substrate. A very small amount (ca. 0.06% of the substrate) of a substance with the properties expected for 2,3-dinor-iPF 3α -VI was detected, but the amount was insufficient for positive identification.
Identification of iPF 3α α α α -VI in urine. We conducted an initial study with 6 subjects (Group I) using a rigorous purification protocol, involving an independent LC purification step prior to mass spectrometric analysis to demonstrate conclusively the presence of iPF 3α -VI in human urine. d6k-PGF 1α -MO was added to the urine along with the internal standard d 4 -iPF 3α -VI to act as a marker to define the elution position of iPF 3α -VI. Samples were then purified by two steps of SPE using reversed-phase and diol stationary phases, followed by LC using MS/MS to detect the d6k-PGF 1α -MO marker. The material eluting immediately after the elution marker was then analyzed by both LC/MS/MS and GC/MS.
Analysis by LC/MS/MS revealed a constituent with an intense ion at m/z 351 (M-1), which gave rise to a daughter ion at m/z 115 (Fig. 7A, lower panel) . We previously found that this daughter ion is characteristic of Group VI iPs and does not occur to an appreciable extent with iPs of other groups (10).
A single major peak was observed with a t R (26.1 min), slightly longer than that of the corresponding ion (355 115) from the tetradeuterated internal standard (t R , 25.7 min, Fig. 7A , upper panel), as expected for iPF 3α -VI. The sample was also analyzed by GC/MS following conversion of iPs to their PFB ester, TMS ether derivatives, which would be expected to give rise to a derivative with a major fragment ion at m/z 567 (M-PFB). When this ion was monitored, a major peak was observed with a t R (13.50 min)
slightly longer than that of the internal standard (t R , 13. Urinary levels of iPF 3α α α α -VI in healthy subjects
In an initial study, the urinary levels of iPF 3α -VI were measured by both the GC/MS and LC/MS/MS methods in six healthy individuals (Group I), including three males and three females. The levels of iPF 3α -VI were between approximately 200 and 300 pg/ml creatinine for five out of the six subjects, with excellent agreement between the two methods (Fig. 8) . However, one subject had substantially higher levels of iPF 3α -VI with both methods, and in this case the level as determined by LC/MS/MS was nearly twice as high as that found using the GC/MS assay (Fig. 8, inset ). This could be due to either overestimation of the internal standard in the GC/MS sample or overestimation of the endogenous signal in the LC/MS/MS sample. Since the internal standard is added at a relatively high level, it is a single, symmetrical peak in all samples, and not likely to be artifactually elevated. Considering the endogenous LC/MS/MS traces (i.e. m/z 351 115), five of the six samples exhibited a single peak with a retention time identical to that of authentic iPF 3α -VI. Only the chromatogram of the outlier sample had an additional peak, raising the possibility that the peak coeluting with the internal standard may be somewhat elevated due to the coelution of an interfering compound that was not removed by the sample prepurification.
A second study was performed in which the urinary levels of iPF 3α -VI were measured by LC/MS/MS in an additional 20 subjects, including 10 males and 10 females (Group II). The average age was 34 ± 13.6, and the average body mass index (weight/height 2 ) was 22.3 ± 2.6. The mean urinary level of iPF 3α -VI among these subjects was 274 ± 201 pg/mg creatinine (mean ± SD). There were no significant differences between males and females ( Fig. 9 ) and no correlation of iPF 3α -VI levels with body mass index (data not shown). There was a tendency for older subjects to have higher levels of iPF 3α -VI, but this was not statistically significant ( in the brain, and may play a role in cognitive development (33). There is also evidence that there is an inverse relationship between the content of EPA/DHA in the diet and the incidence of depression (25) .
Like AA, EPA and DHA can be converted into a series of isoprostanes which, in the case of DHAderived iPs, have been termed neuroprostanes (34). However, prior to the present study, no assays to measure the in vivo production of F 3 -iPs derived from EPA through the measurement of urinary levels were available. Although nPs can be measured in brain tissue, an attempt to measure F 4 -nPs by GC/MS in the urine of patients suffering from Alzheimer's disease found them to be undetectable (20) . We selected Group VI F 3 -iPs and F 4 -nPs as our initial targets for detection in biological fluids because we previously observed that among AA-derived iPs, Group VI iPs such as iPF 2α -VI 2 and 8,12-iso-iPF 2α -VI, are the most abundant in human urine (2, 8) . Because of the close structural analogy of iPF 3α -VI 3 and nPF 4α -VI to iPF 2α -VI 2 ( Fig. 1) , it would seem likely that this would also be the case for Group VI F 3 -iPs and F 4 -nPs.
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As DHA is the most abundant PUFA in the brain, we initially sought to measure urinary nPF 4α -VI levels as an in vivo indicator of its peroxidation. Such biomarkers might be used to titrate the response to ω-3s
in interventional studies to assess their value in the assessment of cognitive function. For this reason we recently developed a method for the total synthesis of nPF 4α -VI and its tetradeutero analog (21) , to permit its quantitation in biological fluids. However, in the present study we were unable to detect nPF 4α -VI in urine by LC/MS/MS. One potential reason for this could be that it was rapidly metabolized in vivo.
Comparison of the structures of iPF 2α -VI and iPF 3α -VI (Fig. 1 ) reveals that the carboxyl side chains of these two molecules are identical, whereas the carboxyl side chain of nPF 4α -VI is elongated and contains an addition double bond at C 4 . Others as well as ourselves have reported that the presence of a hydroxyl group in the 5-position of the carboxyl side chain of leukotrienes and iPs can have a marked effect on their metabolic fates (9,35,36). 5-Hydroxyeicosanoids are resistant to β-oxidation, probably because the 5-hydroxyl group interacts with the carboxyl group, thus limiting access of the enzymes involved in this process. It is this assumption that 5-hydroxy-iPs would be resistant to β-oxidation that led us originally to focus on AA-derived Group VI isoprostanes as we suspected that they would be more abundant in urine than the more commonly measured Group III iPs, and hence easier to discover and measure. We therefore reasoned that the greater distance between this hydroxyl group and the C 1 carboxylic acid group in nPF 4α -VI may result in less protection against β-oxidation compared to iPF 2α -VI and iPF 3α -VI. We compared the extent of β-oxidation of iPF 3α -VI and nPF 4α -VI in vitro by rat liver homogenates to test this hypothesis. In contrast to iPF 3α -VI, which was highly resistant to β-oxidation, nPF 4α -VI was a good substrate for this process, being converted to iPF 3α -VI (i.e. III, which has a 7-carbon carboxylic acid side chain without a hydroxyl group. Under identical reaction conditions, only 3.6% of iPF 2α -III was converted to the dinor metabolite, along with an additional 2.2% to the dihydro-dinor compound (data not shown). This suggests that nPF 4α -VI is particularly prone to β-oxidation at C 1 , providing a possible explanation for our inability to identify this substance in human urine. Others, too, have been unable to measure neuroprostane formation in the urine of AD patients (20) .
The metabolism argument presented here is strengthened by the finding that iPF 2α -III is metabolized in vivo, with a major (29%) urinary metabolite being the dinor dihydro derivative (37) . We and others have also studied this metabolic step (38) (39) (40) . Because nPF 4α -VI is a much better substrate than iPF 2α -III for β-oxidation, we would expect its rate of in vivo metabolism to be several-fold higher, hence explaining the lack of nPF 4α -VI in urine. We were unable to identify any dinor-nPF 4α -VI in incubations with rat liver homogenates, indicating that the 4,5-double bond of nPF 4α -VI was completely reduced. This is presumably due to the formation of the ∆ 2,4 -conjugated diene 22, followed by reduction to the ∆ differing principles of separation and detection between the GC and LC methods described above, there was very good agreement in the urinary levels of iPF 3α -VI between the two methods, providing conclusive evidence for the identification of this iP.
In contrast to the extensive amount of information available on the biological activities of the enzymatically derived prostaglandins and leukotrienes, relatively little is known about the bioactivities of iPs. Although a limited number of studies have been performed on certain iPs derived from AA, it is not yet known whether iPs derived from EPA and DHA have biological activities. We have shown that exogenous iPF 2α -III can activate the thromboxane receptor in platelets and the vasculature in vivo (43) and that 8,12-iso-iPF 2α -III can activate the receptor for PGF 2α in vitro (44, 45) . However, it is unknown whether these iPs function as endogenous receptor ligands at the concentrations formed in vivo. It would be of interest to determine whether iPs derived from EPA and DHA are also biologically active and to compare their effects with those of AA-derived iPs.
The present data raise several important questions. Does the measurement of iPF 3α -VI in urine of normal volunteers reflect two sources of iPs; namely, unmetabolized iPF 3α -VI derived from EPA and the dinor dihydro metabolite of the neuroprostane nPF 4α -VI? If this is true, measurement of iPF 3α -VI could be an excellent index of the combined endogenous autooxidation of EPA and DHA, and might reflect a process of relevance to disease progression in syndromes of neurodegeneration, such as Alzheimer's disease.
Recently, F 4 -neuroprostanes have been detected in brain tissue (19, 46) . However, the measurement of changes in neuroprostane levels in urine as an index of Alzheimer's disease has not been successful (20) .
On the basis of the present results, it would seem likely that this can be explained by the β-oxidation of 
